Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Other Key Findings of This Review
No randomized trial or observational study evaluated the comparative effectiveness of current antiviral treatment regimens for chronic hepatitis C virus (HCV) infection on improving long-term clinical outcomes. No randomized trial or observational study evaluated the comparative effectiveness of current antiviral treatment regimens for chronic HCV infection on clinical outcomes in patients stratified by HCV genotype, age, race, sex, stage of disease, genetic markers, or other factors. The strength of evidence for these findings was rated insufficient.
Three trials that compared current antiviral regimens found no differences in risk of short-term mortality but reported very few (20 total) events. The strength of evidence for this finding was rated low.
Studies found that a sustained virologic response (SVR), when compared with no SVR, was associated with greater improvement in measures related to quality of life (generic or disease-specific) 24 weeks after antiviral treatment. Differences averaged less than 5 to 10 points on various SF-36 domains. The strength of evidence for this finding was rated low. All nine supporting studies were of poor quality and were characterized by failure to adjust for confounders, high loss to followup, and failure to blind patients to SVR status.
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.